Nalfurafine hydrochloride for refractory pruritus in peritoneal dialysis patients: a phase III, multi-institutional, non-controlled, open-label trial

Nalfurafine hydrochloride for refractory pruritus in peritoneal dialysis patients: a phase III, multi-institutional, non-controlled, open-label trial

Abstract Background Nalfurafine hydrochloride (“nalfurafine”), the world’s first selective oral κ-receptor agonist for improving pruritus, is approved in Japan for the treatment of pruritus resistant to existing treatments in hemodialysis (HD) or chronic liver disease patients. Peritoneal dialysis (...

Full description

Bibliographic Details
Main Authors: Hidetomo Nakamoto, Takanori Oh, Masahiro Shimamura, Eiji Iida, Sadanobu Moritake
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Renal Replacement Therapy
Subjects:
Nalfurafine
κ-receptor agonist
Peritoneal dialysis
Pruritus
Refractory
Visual analog scale
Online Access:http://link.springer.com/article/10.1186/s41100-017-0133-8

Internet

http://link.springer.com/article/10.1186/s41100-017-0133-8

Similar Items